Literature DB >> 19411258

Mid-term results of a closed biatrial procedure using bipolar radiofrequency ablation concomitantly performed with non-mitral cardiac operations.

Takeshi Miyairi1, Sumio Miura, Ikutaro Kigawa, Haruo Yamauchi, Sachito Fukuda, Sen Yachi, Kazuhiro Hara.   

Abstract

The long-term success rate of the Cox maze III procedure is excellent, although it has not been widely adopted because of the need for extensive incisions of the atria. In this study, we report our experience with a closed biatrial procedure using bipolar radiofrequency (RF) ablation for treating atrial fibrillation (AF) during non-mitral cardiac operations. Beginning in December 2004, a total of 19 patients underwent a closed biatrial procedure with bipolar RF energy. All the patients had a maze procedure plus a concomitant non-mitral operation. Except for several stabs to introduce the bipolar device, no incisions were made in either atrium. The first six patients were investigated with 64-slice multidetector computed tomography (MDCT), six months after the operation. Patients were followed-up monthly with a clinical examination and electrocardiography. There were no operative deaths. MDCT showed no evidence of coronary sinus stenosis. At one year of follow-up, 93% of the patients (14/15) were in sinus rhythm. The closed biatrial procedure using bipolar RF ablation is safe and effective in treating AF during open-heart surgery. This could be particularly beneficial for patients with AF who are undergoing a cardiac surgical procedure without opening the left atrium.

Entities:  

Mesh:

Year:  2009        PMID: 19411258     DOI: 10.1510/icvts.2008.195149

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  1 in total

1.  Short-term and mid-term effects of radiofrequency ablation in mitral valve surgery in patients with different left atrial sizes.

Authors:  Ming-Hui Yao; Chong-Lei Ren; Lin Zhang; Liang-Gang Li; Sheng-Li Jiang
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.